$NKTR Cashflow Statement | Understand Stock

$NKTR

$38.55 +$0.58 (1.53%) Close

$NKTR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to the sales of future royalties
Non-cash interest expense on liabilities related to sales of future royalties
Loss on revaluation of liability related to the sale of future royalties
Change in fair value of development derivative liability
Non-cash research and development expense
Loss from equity method investment
Stock-based compensation
Depreciation and amortization
Deferred income tax expense
Impairment of right-of-use assets and property, plant and equipment
Impairment of goodwill
Gain on sale of the Huntsville manufacturing facility
(Gain) loss on sale or disposal of property, plant and equipment, net
Impairment of advance payments to contract manufacturers and equipment for terminated program
Provision for net realizable value of inventory
Foreign currency translation adjustment
Amortization of premiums (discounts), net and other non-cash transactions
Amortization of premiums (discounts), net
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Operating leases, net
Other assets
Accounts payable
Accrued compensation
Accrued expenses
Deferred revenue

Net cash used in operating activities
Cash flows from investing activities:
Purchases of investments
Maturities of investments
Proceeds from sale of the Huntsville manufacturing facility, net
Sales of investments
Proceeds (payments) relating to the sale of the Huntsville manufacturing facility, net
Purchases of property, plant and equipment
Sales of property, plant and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities:
Proceeds from sale of future royalties, net of $3.8 million of transaction costs
Repayment of senior notes
Cash receipts from development derivative liability
Proceeds from offering, net
2025 Secondary Public Offering
At-the-Market Offering
Payments of offering costs associated with issuance of common stock
Proceeds from issuance of TCG pre-funded warrant
Proceeds from sale of future royalties
Repurchase of common stock from Bristol-Myers Squibb
Proceeds from shares issued under equity compensation plans and TCG pre-funded warrant
Net cash provided by financing activities

Effect of foreign exchange rates on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Non-cash investing and financing activities:
Fair value of equity method investment in Gannet BioChem received in exchange for sale of Huntsville manufacturing facility
Transaction costs and net working capital adjustment for sale of Huntsville manufacturing facility included in accounts payable and accrued expenses
Supplemental disclosure of cash flow information:
Cash paid for interest
Operating lease right-of-use assets recognized in exchange for lease liabilities
Accounts receivable recognized in exchange for long-term liabilities
Cash paid (refund) for income taxes, net

Comments